FDA Brief

Warning letters Drugs

FDA warning letter to

Revive Rx LLC dba Revive Rx Pharmacy

High riskIssued Sep 22, 2025Posted Dec 23, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Revive Rx Pharmacy over insanitary production of sterile compounded drugs, citing contamination risks.

What happened

FDA inspected Revive Rx's Houston pharmacy from January 27, 2025, to February 7, 2025, and issued a Form FDA 483 (inspection observations). The investigator found sterile drug products exposed to worse than required cleanroom air quality, microbial contamination in the sterile processing area, and inadequate sterility process tests, airflow studies, and cleanroom monitoring. FDA reviewed the firm's March 2025 responses and found several corrective actions deficient or missing supporting documentation.

What FDA found

  1. Sterile drug products were exposed to air worse than the required cleanroom quality.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The firm did not adequately evaluate or correct microbial contamination found in the sterile processing area.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. Sterility process tests were not run under the most challenging conditions, so FDA lacks assurance the firm can make sterile drugs safely.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  4. Airflow studies under dynamic conditions were inadequate to show one-way airflow in the sterile processing area.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  5. The firm failed to sterilize certain equipment by routine sterilization cycles and to protect it from contamination on air lines and vents.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  6. Routine cleanroom monitoring in the sterile processing area was inadequate, including inside certain units.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]

What FDA wants

FDA asks Revive Rx to notify it in writing within 15 working days of the specific steps taken to address the violations, prevent recurrence, and include related documentation; if it cannot complete the work in that time, it must explain the delay and give a timeline.

Who should pay attention

  • patients receiving compounded sterile drugs
  • healthcare providers who prescribe or administer compounded sterile drugs
  • compounding pharmacies and facilities that make sterile drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk